Fahri E. Sahin

Ege, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Dose or Timing? The Role of Prophylaxis in Preventing Joint Bleeds in Hemophilia: A Cross-Generational Comparative Analysis.

Dose or Timing? The Role of Prophylaxis in Preventing Joint Bleeds in Hemophilia: A Cross-Generational Comparative Analysis.

Journal: The Eurasian journal of medicine

Published: July 16, 2026

The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries - For Whom, by Whom and Where?

The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries - For Whom, by Whom and Where?

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: June 12, 2026

Acquired Hemophilia A Associated with Post-Essential Thrombocythemia Myelofibrosis: A Rare Autoimmune Bleeding Complication

Acquired Hemophilia A Associated with Post-Essential Thrombocythemia Myelofibrosis: A Rare Autoimmune Bleeding Complication

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: April 10, 2026

Investigation of kinesiophobia, physical activity, quality of life, depression and anxiety level in adult people with hemophilia: A frequency-matched case-control study.

Investigation of kinesiophobia, physical activity, quality of life, depression and anxiety level in adult people with hemophilia: A frequency-matched case-control study.

Journal: Journal of back and musculoskeletal rehabilitation

Published: March 20, 2026

Advanced Molecular Analysis in Hemophilia A in a Single Step: Next Generation Sequencing (NGS) and Copy Number Variation (CNV) Analysis.

Advanced Molecular Analysis in Hemophilia A in a Single Step: Next Generation Sequencing (NGS) and Copy Number Variation (CNV) Analysis.

Journal: International journal of laboratory hematology

Published: January 07, 2026

Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients.

Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients.

Journal: Annals of hematology

Published: August 13, 2025

Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.

Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.

Journal: Blood

Published: August 05, 2025

Efficacy and safety of vemircopan as monotherapy in patients with paroxysmal nocturnal hemoglobinuria.

Efficacy and safety of vemircopan as monotherapy in patients with paroxysmal nocturnal hemoglobinuria.

Journal: Blood advances

Published: July 11, 2025

Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial.

Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 17, 2025

Haemophilia-Related Pain: A Bibliometric and Content Analysis of Research Trends and Key Themes.

Haemophilia-Related Pain: A Bibliometric and Content Analysis of Research Trends and Key Themes.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 14, 2025

Simultaneous total hip and knee arthroplasties in hemophilic arthropathy: series of 5 cases.

Simultaneous total hip and knee arthroplasties in hemophilic arthropathy: series of 5 cases.

Journal: Acta orthopaedica et traumatologica turcica

Published: January 29, 2025

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

Journal: Annals of hematology

Published: January 17, 2025

Showing 1-12 of 89

Last Updated: 09/26/2026